Contrary to metformin, which was activated by adenosine 5‘-monophosphate-activated protein kinase (AMPK), EVT-701 is driven by Liver kinase B1 (LKB1) status, making EVT-701 suitable as a combination therapy to counteract tumor metabolic changes. Here, STK11 is linked to neoplasm.